PF4 and myeloid sarcoma: This finding underscores the potential therapeutic value of inhibiting the mtROS/HIF-2α signaling pathway and ameliorating the hypoxic microenvironment to attenuate the detrimental effects of CXCL4 in MS and other CXCL4-driven inflammatory disorders.